Dec 20, 2021
Kathy Lee-Sepsick is the President, CEO, and Founder of Femasys, and not looking at minor levels of improvement in women's healthcare, but products and technologies that change the standard of care. With a focus on reproductive health, they are looking at infertility as well as a permanent birth control option for women.
Kathy explains, "So one of our major products is called FemVue. And what we did here is another example of what we're trying to do in these other product categories. We have developed a way to move an essential test for infertility diagnosis from radiology back to her GYN, utilizing ultrasound. So FemVue offers a saline and air contrast, or we call it bubbles, where those bubbles enable the evaluation and viewing of her fallopian tubes, which is suspect when a physician is evaluating all potential infertility factors."
"And at the same time, we are also advancing through clinical trial work, our FemBloc solution, which is our permanent birth control option for women. And both of those are delivered in an office environment. OBGYNs are performing the FemBloc procedure, and that's performed domestically as well in an active clinical trial."
@FemasysInc #ReproductiveHealth #WomensHealth #BirthControl #Infertility #FemBloc #FemVue
